Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AIMP2 | Q13155 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 7/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824059 | 0.90 | MAPT (0.45) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL19766407 | 0.86 | PLK1 (0.45) | JAK2HDAC1HDAC6EGFRABL1 | |
| SCHEMBL12352801 | 0.85 | PIK3CG (0.47) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL11955402 | 0.84 | ABL1 (0.47) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL1098726 | 0.83 | ABL1 (0.46) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL824072 | 0.83 | PIK3CA (0.44) | JAK2EGFRABL1BCRSRC | |
| SCHEMBL1097901 | 0.82 | ABL1 (0.52) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL14022863 | 0.81 | ABL1 (0.49) | AIMP2JAK2HDAC1HDAC6EGFR | |
| SCHEMBL13355584 | 0.76 | MAPT (0.46) | AIMP2JAK2EGFRABL1BCR | |
| SCHEMBL823940 | 0.73 | SYK (0.39) | AIMP2JAK2EGFRABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9120815-B2 | Solid state forms of macrocyclic kinase inhibitors | TRAGARA PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120815-B2 | Solid state forms of macrocyclic kinase inhibitors | TRAGARA PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20130150378-A1 | SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS | Cothera Bioscience, Inc. (KY) | 2013-06-13 | — | — | US | disclosed |
| US-20130150378-A1 | SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS | Cothera Bioscience, Inc. (KY) | 2013-06-13 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| EP-1951730-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*Bio Pte Ltd (SG) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | AIMP2 2255/4885JAK2 692/4885HDAC1 2698/4885 |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | AIMP2 2255/4885JAK2 692/4885HDAC1 2698/4885 |
| US-20130150378-A1 | SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS | MAP3K20, MAP3K15, MAP3K1 | AIMP2 4277/4885JAK2 91/4885HDAC1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.